In an increasingly uncertain market, where concentration risk looms large, savvy investors are seeking refuge in quality blue-chip stocks. With about 50% of the market's earnings stemming from the top ...
Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...
2d
'This is a great opportunity to get, what we call, a dividend growing stock': Nesbitt on Abbvie Inc.
Don Nesbitt, senior portfolio manager at F/m Investments, joins BNN Bloomberg to share his Hot Picks in healthcare.
The Harbor Health Care ETF MEDI is now three years old and has performed so well that it has been rated five stars (the highest rating) within Morningstar's U.S. Fund Health category. The ...
AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded ...
AbbVie Inc. (NYSE: ABBV) garnered a ‘Buy’ rating from analyst Rajesh Kumar at HSBC, suggesting a robust upside potential for investors. The analyst set a price target of $265, indicating a notable ...
Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...
Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:30 AM ESTCompany ParticipantsDavid Amsellem - MD & Senior ...
Zacks Investment Research on MSN
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
AbbVie remains a Strong Buy due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline.
AbbVie, Amgen, and IBM are among 2025’s top dividend performers, each up more than 30% while offering solid yields and steady income.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback